The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

Dck  -  deoxycytidine kinase

Rattus norvegicus

Synonyms: Deoxycytidine kinase, dCK
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Dck

  • We also demonstrate that ara-C treatment of established intradermal and intracerebral gliomas transduced with dCK results in significant antitumor effects in vivo [1].
  • Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 [2].
  • (1) Deoxycytidine kinase activity increased in a transformation- and progression-linked fashion in rat hepatomas of different proliferation rates [3].
  • The activity of deoxycytidine kinase (EC 2.7.1.74), an important pyrimidine salvage enzyme, was elevated 5- to 30-fold in human ovarian carcinoma and OVCAR-5 cells, in human colon carcinoma and HT-29 cells, in rat hepatoma 3924A solid tumors and cells, and in rat sarcoma as compared with the respective control normal cells [4].
 

High impact information on Dck

  • The rate-limiting step in intracellular ara-C activation is phosphorylation of the prodrug by deoxycytidine kinase (dCK) [1].
  • Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo [1].
  • These data suggest that viral vector transduction of the dCK gene followed by treatment with ara-C represents a new chemosensitization strategy for cancer gene therapy [1].
  • Deficiency of functional deoxycytidine kinase (dCK) is a common characteristic for in vitro resistance to cytarabine (AraC) [5].
  • In control samples from healthy donors (PHA T cells and bone marrow), only wild-type dCK complementary DNA (cDNA) was amplified [5].
 

Chemical compound and disease context of Dck

  • Gemcitabine (2'-2'-difluorodeoxycytidine (dFdC)) is a deoxycytidine analogue that is effective against solid tumors, including lung cancer and ovarian cancer. dFdC requires the phosphorylation by deoxycytidine kinase (dCK) as a primary step in its activation [2].
  • (6) Actinomycin treatment of rats carrying hepatomas yielded a t1/2 of 5.8 hr for deoxycytidine kinase activity in the tumor which was one of the shortest in the examined enzymes of purine and pyrimidine biosynthesis [3].
  • (5) Cycloheximide treatment of rats carrying hepatomas yielded a t1/2 = 3.4 hr in the tumor for deoxycytidine kinase activity which was the shortest among the examined enzymes of purine and pyrimidine biosynthesis [3].
 

Biological context of Dck

 

Anatomical context of Dck

  • Northern blot analysis of rat tissues revealed high expression of a 4.1-kb Dck transcript in the thymus, whereas spleen, liver and lung samples showed weak expression of the gene [6].
  • As a result, the activity ratio of dCK/dCDA (a potential indicator of chemosensitivity) was decreased in the normal fibroblasts but increased in the transformed cells by DHA [8].
  • Deoxycytidine kinase activity in human HL-60 cells was inhibited by the end product, dCTP, with IC50 = 3 microM; dCTP elevated the Km for deoxycytidine from 0.35 to 0.9 mM. dTTP reversed the inhibition by dCTP.(ABSTRACT TRUNCATED AT 250 WORDS)[4]
 

Associations of Dck with chemical compounds

 

Other interactions of Dck

 

Analytical, diagnostic and therapeutic context of Dck

References

  1. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Manome, Y., Wen, P.Y., Dong, Y., Tanaka, T., Mitchell, B.S., Kufe, D.W., Fine, H.A. Nat. Med. (1996) [Pubmed]
  2. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000. Al-Madhoun, A.S., van der Wilt, C.L., Loves, W.J., Padron, J.M., Eriksson, S., Talianidis, I., Peters, G.J. Biochem. Pharmacol. (2004) [Pubmed]
  3. Regulation of deoxycytidine kinase activity and inhibition by DFDC. Weber, G., Singhal, R.L., Abonyi, M., Prajda, N., Hata, Y., Szekeres, T., Yeh, A., Look, K.Y. Adv. Enzyme Regul. (1993) [Pubmed]
  4. Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine. Singhal, R.L., Yeh, Y.A., Szekeres, T., Weber, G. Oncol. Res. (1992) [Pubmed]
  5. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Veuger, M.J., Honders, M.W., Landegent, J.E., Willemze, R., Barge, R.M. Blood (2000) [Pubmed]
  6. Cloning of the Dck gene encoding rat deoxycytidine kinase. Stegmann, A.P., Honders, M.W., Willemze, R., Landegent, J.E. Gene (1994) [Pubmed]
  7. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. Stegmann, A.P., Honders, W.H., Willemze, R., Ruiz van Haperen, V.W., Landegent, J.E. Blood (1995) [Pubmed]
  8. Modifications of deoxycytidine kinase and deaminase activities by docosahexaenoic acid in normal and transformed rat fibroblasts. Cha, M.C., Meckling-Gill, K.A. Biochem. Pharmacol. (2002) [Pubmed]
  9. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells. Richel, D.J., Colly, L.P., Arkesteijn, G.J., Arentsen-Honders, M.W., Kerster, M.G., ter Riet, P.M., Willemze, R. Cancer Res. (1990) [Pubmed]
  10. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. Stegmann, A.P., Honders, M.W., Kester, M.G., Landegent, J.E., Willemze, R. Leukemia (1993) [Pubmed]
  11. Deoxycytidine kinase and thymidine kinase activities in rat brain. Singhal, R.L., Weber, G. Oncol. Res. (1993) [Pubmed]
  12. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Stegmann, A.P., Honders, M.W., Hagemeijer, A., Hoebee, B., Willemze, R., Landegent, J.E. Ann. Hematol. (1995) [Pubmed]
  13. A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells. Veuger, M.J., Honders, M.W., Landegent, J.E., Willemze, R., Barge, R.M. Leukemia (2000) [Pubmed]
 
WikiGenes - Universities